Investment Firm Takes Major Position in Quantum Biopharma Amid Strategic Advisory Role

Rhea-AI Filing Summary

Malone Wealth Ventures LLC has filed a Schedule 13D/A amendment disclosing a 17% ownership stake (580,806 shares) in Quantum Biopharma. The filing reveals significant recent share accumulation through multiple transactions between June 13-20, 2025, with purchase prices ranging from $19.10 to $37.59 per share.

Key details:

• Kevin Malone serves as Advisor to Quantum Biopharma's Board of Directors
• Received 90,000 shares in total as compensation (30,000 initial grant plus 60,000 additional)
• Has sole voting power over 52,265 shares and sole dispositive power over 580,806 shares
• Shares acquired through client funds (Malone Wealth Ventures) and board advisor compensation

The filing indicates potential influence over company control, with Malone participating in discussions regarding strategic direction, financing, capitalization, and corporate governance. The advisory agreement was established on April 15, 2025, with additional RSUs available based on performance goals.

Positive

• Significant stake acquisition: Malone Wealth Ventures LLC has accumulated a 17% ownership position in Quantum Biopharma Ltd., representing substantial institutional confidence
• Active accumulation pattern: The firm made consistent large purchases at increasing price points ($19-$37 range) over June 13-20, 2025, indicating strong conviction
• Strategic board involvement: Kevin Malone received 90,000 shares as compensation for Board Advisory role, suggesting active involvement in company direction
• Price appreciation: Share price showed strong upward momentum during accumulation period, rising from $19.10 to $37.59 (~97% increase)

Negative

• High concentration risk: Single investment advisor controlling 17% of outstanding shares could create selling pressure if position is reduced
• Rapid price increase: The sharp rise in share price (~97% in one week) may indicate unsustainable momentum or speculation

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)

Quantum Biopharma Ltd.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

74764Y205

(CUSIP Number)

Malone Wealth Ventures
9201 W State St. Ste 126,
Boise, ID, 83714
2089854526

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/12/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 74764Y205

1

Name of reporting person

Malone Wealth Ventures LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

IDAHO

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 52,265.00
8	Shared Voting Power
9	Sole Dispositive Power 580,806.00
10	Shared Dispositive Power

11

Aggregate amount beneficially owned by each reporting person

580,806.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

17.0 %

14

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person:

Les Gro

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock
(b)	Name of Issuer: Quantum Biopharma Ltd.
(c)	Address of Issuer's Principal Executive Offices: 55 UNIVERSITY AVENUE, SUITE 1003, 55 UNIVERSITY AVENUE, SUITE 1003, TORONTO, ONTARIO, CANADA , M5J 2H7.
Item 1 Comment: Les Gro
Item 2.	Identity and Background
(a)	This Schedule 13D is being filed by Kevin Malone, an individual and a U.S. citizen, and Malone Wealth Ventures LLC, a fiduciary investment advisory firm.
(b)	9201 W State St. Ste 126, Boise, ID, 83714
(c)	Kevin Malone is the President and CEO of Malone Wealth Ventures LLC, a fiduciary investment advisory firm located at 9201 W State St. Ste 126, Boise, ID 83714.
(d)	No
(e)	No
(f)	United States
Item 3.	Source and Amount of Funds or Other Consideration
	The securities reported herein were acquired through (i) open market purchases made using client funds over which Malone Wealth Ventures LLC has discretionary investment authority, and (ii) a grant of 30,000 shares issued directly to Kevin Malone as compensation for his role as Advisor to the Board of Directors of Quantum Biopharma Inc., pursuant to a consulting agreement between Mr. Malone and the issuer. An additional 60,000 share grant was received based on continuation of work. At this time, no other grants have been discussed in the future.
Item 4.	Purpose of Transaction
	The securities were acquired for investment purposes. Kevin Malone serves as Advisor to the Board of Directors of the issuer and may, in such capacity, participate in discussions relating to strategic direction, financing, capitalization, or corporate governance. As such, the Reporting Persons may be deemed to have an intent to influence the control of the issuer. The Reporting Persons may, from time to time, acquire additional securities of the issuer or dispose of some or all of the securities reported herein, depending on market conditions, investment strategies, or other factors. Except as set forth herein, the Reporting Persons do not currently have any plans or proposals which relate to or would result in any of the actions enumerated in paragraphs (a) through (j) of Item 4.
Item 5.	Interest in Securities of the Issuer
(a)	580,806 and 17%
(b)	52,265
(c)	The following transactions in the Common Stock of the issuer were effected by Malone Wealth Ventures LLC on behalf of advisory clients during the 60 days preceding the filing of this Schedule 13D/A. All transactions were open market purchases executed on public exchanges: June 13, 2025 - Purchased 1,000 shares at $19.10 per share June 13, 2025 - Purchased 10 shares at $19.25 per share June 13, 2025 - Purchased 100 shares at $18.80 per share June 13, 2025 - Purchased 24 shares at $19.11 per share June 13, 2025 - Purchased 1,000 shares at $19.83 per share June 13, 2025 - Purchased 1,000 shares at $21.10 per share June 13, 2025 - Purchased 250 shares at $20.65 per share June 13, 2025 - Purchased 1,000 shares at $20.65 per share June 13, 2025 - Purchased 1,000 shares at $20.55 per share June 13, 2025 - Purchased 1,000 shares at $20.40 per share June 13, 2025 - Purchased 1,000 shares at $20.92 per share June 13, 2025 - Purchased 200 shares at $20.70 per share June 13, 2025 - Purchased 50 shares at $20.70 per share June 13, 2025 - Purchased 25 shares at $20.70 per share June 13, 2025 - Purchased 1,000 shares at $20.70 per share June 13, 2025 - Purchased 40 shares at $20.70 per share June 13, 2025 - Purchased 30 shares at $20.70 per share June 13, 2025 - Purchased 40 shares at $20.70 per share June 13, 2025 - Purchased 1,000 shares at $20.40 per share June 13, 2025 - Purchased 1,000 shares at $20.30 per share June 13, 2025 - Purchased 1,000 shares at $20.08 per share June 13, 2025 - Purchased 1,000 shares at $19.30 per share June 13, 2025 - Purchased 1,000 shares at $19.40 per share June 13, 2025 - Purchased 1,000 shares at $19.30 per share June 13, 2025 - Purchased 5,000 shares at $19.70 per share June 16, 2025 - Purchased 1,000 shares at $21.02 per share June 16, 2025 - Purchased 50 shares at $21.02 per share June 16, 2025 - Purchased 100 shares at $21.02 per share June 16, 2025 - Purchased 80 shares at $21.02 per share June 16, 2025 - Purchased 30 shares at $21.02 per share June 16, 2025 - Purchased 200 shares at $21.02 per share June 16, 2025 - Purchased 200 shares at $21.02 per share June 16, 2025 - Purchased 50 shares at $21.02 per share June 16, 2025 - Purchased 1,000 shares at $21.57 per share June 16, 2025 - Purchased 1,000 shares at $21.26 per share June 16, 2025 - Purchased 100 shares at $21.58 per share June 17, 2025 - Purchased 1,000 shares at $26.19 per share June 17, 2025 - Purchased 1,000 shares at $24.90 per share June 17, 2025 - Purchased 1,000 shares at $24.00 per share June 17, 2025 - Purchased 2 shares at $25.02 per share June 17, 2025 - Purchased 50 shares at $25.06 per share June 17, 2025 - Purchased 400 shares at $25.06 per share June 17, 2025 - Purchased 1,000 shares at $25.06 per share June 17, 2025 - Purchased 12 shares at $25.02 per share June 17, 2025 - Purchased 50 shares at $25.02 per share June 17, 2025 - Purchased 15 shares at $25.06 per share June 17, 2025 - Purchased 100 shares at $25.02 per share June 17, 2025 - Purchased 11 shares at $25.00 per share June 17, 2025 - Purchased 40 shares at $25.02 per share June 17, 2025 - Purchased 200 shares at $25.06 per share June 17, 2025 - Purchased 400 shares at $25.06 per share June 17, 2025 - Purchased 190 shares at $25.06 per share June 17, 2025 - Purchased 25 shares at $25.06 per share June 17, 2025 - Purchased 110 shares at $25.06 per share June 17, 2025 - Purchased 15 shares at $25.02 per share June 17, 2025 - Purchased 20 shares at $25.02 per share June 17, 2025 - Purchased 40 shares at $25.06 per share June 17, 2025 - Purchased 1,000 shares at $25.50 per share June 18, 2025 - Purchased 100 shares at $27.00 per share June 18, 2025 - Purchased 1,000 shares at $27.95 per share June 18, 2025 - Purchased 1,000 shares at $29.17 per share June 18, 2025 - Purchased 1,000 shares at $30.80 per share June 18, 2025 - Purchased 1,000 shares at $31.00 per share June 18, 2025 - Purchased 1,000 shares at $31.31 per share June 18, 2025 - Purchased 119 shares at $30.88 per share June 18, 2025 - Purchased 1,000 shares at $30.24 per share June 18, 2025 - Purchased 20 shares at $31.20 per share June 20, 2025 - Purchased 1,000 shares at $36.71 per share June 20, 2025 - Purchased 1,000 shares at $37.55 per share June 20, 2025 - Purchased 1,000 shares at $37.50 per share June 20, 2025 - Purchased 1,000 shares at $37.35 per share June 20, 2025 - Purchased 1,000 shares at $36.26 per share June 20, 2025 - Purchased 1,000 shares at $37.59 per share June 20, 2025 - Purchased 1,000 shares at $35.30 per share All trades were executed by Malone Wealth Ventures LLC and were directed all at client's requests.
(d)	The clients of Malone Wealth Ventures LLC, as beneficial owners of the securities managed on a discretionary basis, have the right to receive dividends and the proceeds from the sale of such securities. None of the individual clients, to the best knowledge of the Reporting Persons, holds more than 5% of the issuer's outstanding shares.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Pursuant to an agreement with the issuer, Quantum Biopharma Inc., Kevin Malone serves as an advisor to the Board of Directors. In connection with this engagement, the Reporting Person received a grant of 30,000 restricted stock units (RSUs), with additional RSUs issuable upon the achievement of certain goals. The Reporting Person disclaims beneficial ownership of the unvested RSUs except to the extent that such rights are vested or become exercisable within 60 days of the date of this filing. Other than as described herein, there are no contracts, arrangements, understandings, or relationships (legal or otherwise) between the Reporting Persons and any other person with respect to any securities of the issuer.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 1 Advisory and Equity Compensation Agreement between Kevin Malone and Quantum Biopharma Inc., dated April 15th, 2025.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Malone Wealth Ventures LLC

Signature:	Kevin M Malone
Name/Title:	President and CEO
Date:	06/23/2025

FAQ

What percentage of Quantum Biopharma (QNTM) shares does Malone Wealth Ventures own as of June 2025?

According to the Schedule 13D/A filing, Malone Wealth Ventures LLC beneficially owns 580,806 shares, representing 17% of Quantum Biopharma's (QNTM) outstanding shares.

How many QNTM shares did Malone Wealth Ventures purchase in June 2025?

Between June 13-20, 2025, Malone Wealth Ventures made numerous purchases totaling approximately 35,000 shares at prices ranging from $19.10 to $37.59 per share through open market transactions.

What is Kevin Malone's role at QNTM and how many restricted stock units (RSUs) did he receive?

Kevin Malone serves as an Advisor to QNTM's Board of Directors. He received an initial grant of 30,000 RSUs and an additional 60,000 share grant based on continued work, per the Advisory and Equity Compensation Agreement dated April 15th, 2025.

What is the purpose of Malone Wealth Ventures' investment in QNTM?

According to Item 4 of the filing, the securities were acquired for investment purposes. As Kevin Malone serves as Advisor to the Board, the Reporting Persons may participate in discussions relating to strategic direction, financing, capitalization, or corporate governance and may be deemed to have intent to influence control of the issuer.

How many QNTM shares does Malone Wealth Ventures have sole voting power over?

According to the filing, Malone Wealth Ventures LLC has sole voting power over 52,265 shares of QNTM stock, while having sole dispositive power over 580,806 shares.